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Conclusion: Increase in adherence to the guidelines leads to decrease in short and mid-
term mortality in STEMI, but the increase in major bleeding complications was noted.
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Background: During acute myocardial infarction (AMI), degranulated platelets adhere
to the monocytes and form monocyte platelet aggregate (MPA). The level of MPA can
therefore reflect the pathological change and indicate the degree of inflammation and
thrombosis in AMI. Recently, MPA assay has been developed for in vivo platelet
function assessment. MPA may act as a biomarker for ACS.
Methods: In this single-center prospective observational study, we recruited 29
consecutive AMI patients and 19 healthy controls. Blood samples in first 24 hrs of
AMI and Day 5 after dual antiplatelet treatment were taken from patients. MPA level
was measured by flow cytometry. MPA in circulating blood were displayed in a dual-
fluorescence dot plot of CD14-FITC and CD41-PE. MPA level of the health subjects
and AMI patients were compared. In wave one analysis, patients were grouped into
high MPA group and low MPA group by upper limit of the normal subjects, in which
baseline characteristics and clinical endpoints between two groups were compared. In
wave two analysis, patients with rising trend of MPA after dual antiplatelet treatment
and patients with decreasing trend of MPA were compared. The endpoint is composite
cardiovascular endpoints of death, recurrent ACS, cardiogenic shock, heart failure and
ventricular tachycardia/ventricular fibrillation (VT/VF) in post AMI day 30.
Results: MPA level in AMI patients (mean= 33) are significantly higher than the
normal health subjects (mean=25). (p<0.05). In wave one analysis, high MPA group
(n=9) and low MPA (n=20) group reaching the endpoint were 55% (n=5) and 30%
(n=6) respectively. (p=0.2). In wave two analysis, rising MPA group (n= 12) showed
58.3 % (n=7) patients reaching endpoint. Decreasing trend MPA group (n=9) showed
11.1% (n=1) patient reaching endpoint. Rising MPA group showed a trend of more
post MI complications compared to decreasing MPA group but statistically, it is not
significant. (p= 0.06).
Conclusion: MPA significantly elevated in AMI patients. There is a trend that high
MPA and rising MPA in AMI patients will have more post MI complications.
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Background: Stenting compared with PTCA for STEMI reduces TVR and target
vessel re-occlusion at 6-12 months. Comparison of outcomes beyond 12 months has
not been studied. We hypothesized that there may be a very late hazard with stenting
vs PTCA due to very late stent thrombosis (ST).
Methods: From 1995-2010 consecutive pts with STEMI were treated with primary
PTCA (n=601) or primary stenting with BMS or DES (n=1594). Clinical and
angiographic follow-up were obtained at 1-16 yrs. Comparable definitions were used
for ST (ARC definite or probable) and lesion thrombosis (LT).
Results: Pts treated with PTCA were older, more often female, had more hypertension,
more 3V CAD, smaller vessels, more TIMI 0-1 flow at initial angiography, and longer
reperfusion times. At 1 yr there were mild trends for lower mortality, MI and ST/LT
with stenting vs PTCA. In landmark analyses after 1 yr, pts treated with stenting vs
PTCA had more very late ST/LT (Figure) and more TV MI but no differences in death
or total MI. Most of the differences in ST/LT and TV MI between stents and PTCA
were due to differences between DES and PTCA with smaller differences between
BMS and PTCA. After adjusting for baseline risk, stents vs PTCA had more very late
ST/LT (HR 2.63, 95% CI 1.40-4.95, p=0.003) and more very late TV MI (HR 2.98,
95% CI 1.68-5.31, p<0.001).
Conclusion: There appears to be a very late hazard with primary stenting compared
with primary PTCA for STEMI with more very late ST/LT and more TV MI. These
data should encourage new strategies for prevention of very late ST with both BMS
and DES including the development of bio-absorbable stents and polymers.
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Background: There is limited contemporary data on factors that predict bleeding in
the setting of primary PCI, and on the impact of bleeding on mortality.
Methods: We identified pts referred for primary PCI from our database. Standard
therapy before catheterization included ASA 160mg, clopidogrel 600mg and UFH 60
u/kg (max 4000). Bleeding was defined as TIMI major/minor bleeding. We used
logistic regression to determine baseline variables associated with bleeding during the
initial hospitalization and all-cause mortality at 180 days.
Results: Between May 2005 and July 2010, 2032 consecutive pts with STEMI were
referred for primary PCI. Primary PCI was performed in 93% of pts and transradial
access was used in 12%. Bivalirudin was used in to 29% of pts and glycoprotein 2b/3a
inhibitors to 36%. Bypass surgery was performed in 4%. TIMI major/minor bleeding
occurred in 14.8% of pts: TIMI major in 4.5% and TIMI minor in 10.3%. Blood
transfusion was needed in 6.3% of pts. Independent predictors of bleeding were Killip
class, anterior STEMI, transfemoral access, age, anemia, serum creatinine, door-to-
balloon time, height and the use of glycoprotein 2b/3a vs. bivalirudin. Mortality at 180
days was 7.7% for the entire group: 18.5% in pts with bleeding vs. 5.6% in pts without
bleeding, p<0.0001. The mortality rate was 24.4% in pts with major bleeding and
15.8% in pts with minor bleeding. The results of the multivariable analysis to determine
predictors of mortality at 180 days are shown in the Table below.
Conclusion: In the real world setting, TIMI major and TIMI minor bleeding are
important predictors of mortality in pts referred for primary PCI. Altering factors that
predict bleeding could lead better clinical outcomes.
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Background: Limited information exists regarding procedural success and clinical
outcomes of patients with prior CABG undergoing PPCI for STEMI. We sought to
compare outcomes in this group.
Methods: Data was analysed from a prospective database on 2322 STEMI patients
undergoing PPCI between 2004-2010 at a London centre. 104 of 2,322 (4.5%) patients
had prior CABG. Information was entered at the time of procedure and outcome
assessed by all-cause mortality information.
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